Title | GENOTYPIC RESISTANCE REDUCED TO VERY LOW LEVELS IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED OVER 2-YEARS WITH TELBIVUDINE (LDT) WHEN CONSIDERING BASELINE CHARACTERISTICS AND ROADMAP | |||
Speaker: | Fabien Zoulim | |||
Author: | F. Zoulim1*, S. Zeuzem2, T. Piratvisuth3, H.L. Chan4, J. Hou5, J. Jia6, S. Bosset7, A. Uddin8, Y. Dong7, A. Trylesinski7 | |||
Affiliation: | 1Head of Viral Hepatitis Research Team, INSERM, Lyon, France, 2Klinikum der Johann-Wolfgang-Goethe-Universitaet, Frankfurt am Main, Germany, 3NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Bangkok, Thailand, 4Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong S.A.R., 5Southern Medical University, Guangzhou, 6Beijing Friendship Hospital, Beijing, China, 7Novartis Pharma, AG, Basel, Switzerland, 8Novartis Pharmaceuticals, East Hanover, NJ, USA. *[email protected] | |||
Background: Baseline HBV DNA, ALT levels and Week 24 HBV DNA levels predict resistance during CHB treatment. | ||||
| HBeAg-positive | HBeAg-negative | ||
Year 1 / Week 52 | N=57 | N=86 | ||
Undetectable serum HBV DNA | 96.5% | 97.7% | ||
HBeAg seroconversion | 39.6% | - | ||
Genotypic resistance | 0% | 0% | ||
| Subgroup analysis* | Mathematical model** | Subgroup analysis* | Mathematical model** |
Year 2 / Week 104 | N=57 | N=55 | N=86 | N=84 |
serum HBV DNA | 89% | 90.9% | 91% | 92.9% |
HBeAg seroconversion | 52% | 53.2% | - | - |
Cumulative genotypic resistance | 1.8 % | 1.8 % | 2.3 % | 2.4 % |
欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) | Powered by Discuz! X1.5 |